Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zidovudine · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Zidovudine | DRUG | - |
| Sargramostim | DRUG | - |
Inclusion Criteria Concurrent Treatment: Allowed: * Minimal local irradiation for tumors. Patients must have: * Diagnosis of AIDS or AIDS related complex (ARC). * Neutropenia, due either to zidovudine (AZT) or HIV infection. * Life expectancy = or \> 6 months. Exclusion Criteria Co-existing C...
Top 20 of 28 competitors
Zidovudine is a small molecule drug being developed for HIV Infections. It is currently in Phase 1 clinical development. The drug is being studied in patients with severe HIV infection and leukopenia, a condition of low white blood cell count.
Zidovudine is being developed by Novartis AG, which trades under the ticker symbol NVS. The company is conducting clinical research on this drug for the treatment of HIV Infections.
Zidovudine is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1/II clinical trial has been completed for this drug.
Zidovudine has one completed clinical trial registered under NCT00002006. This was a Phase 1/II pilot study evaluating the drug in combination with Rhu GM-CSF in patients with severe HIV infection and leukopenia. The trial was conducted in the United States.
Yes, Zidovudine is also known as AZT, which stands for azidothymidine. The clinical trial NCT00002006 refers to the drug as azidothymidine (AZT), confirming that Zidovudine and AZT are the same drug.